Searched for: in-biosketch:yes
person:bersha03
Epidemiological trends of HIV among individuals aged 15-54 years in South Africa from 2004 to 2025: a population-based, longitudinal cohort study
Okango, Elphas; Otto, Margot; Tram, Khai Hoan; Dobra, Adrian; Kim, Hae-Young; Mee, Paul; Inghels, Maxime; Cuadros, Diego; Bershteyn, Anna; Gareta, Dickman; Bärnighausen, Till; Tomita, Andrew; Mwambi, Henry; Herbst, Kobus; Tanser, Frank Courteney
BACKGROUND:South Africa has mounted the largest HIV prevention and treatment programme in history, delivering substantial gains in survival and prevention of new HIV infections; however, service disruptions and recent funding losses might jeopardise these successes. There is a scarcity of high-quality, population-based empirical evidence on key epidemic metrics needed to accurately gauge recent progress towards epidemic control in South Africa. We aimed to evaluate recent progress towards HIV epidemic control in South Africa by quantifying long-term trends in key epidemic control metrics in a large population-based cohort in rural KwaZulu-Natal, South Africa. METHODS:In this population-based, longitudinal cohort study, we used prospectively collected HIV testing, sociodemographic, behavioural, and population viral load data from the Africa Health Research Institute (AHRI) health and demographic surveillance system in rural KwaZulu-Natal from 2003 to 2025. Population-based HIV surveys (encompassing individual health interview and HIV testing) take place annually in all consenting resident individuals aged 15 years or older. We used Poisson regression models to quantify trends in directly observed HIV incidence in repeat testers (aged 15-54 years) who had initially tested negative for HIV and subsequently received at least one valid HIV test result. We further analysed 11 rounds of population viral load testing conducted between 2011 and 2025. We used generalised estimating equations to quantify population viral suppression metrics and calculated trends in the incidence-to-prevalence ratio, a key metric for evaluating progress towards epidemic control. FINDINGS/RESULTS:Between June 24, 2003, and May 22, 2025, across the population cohort, 59 806 (65·4%) of 91 367 contacted individuals aged 15-54 years consented to participate at least once in population-based HIV testing. Of those tested, 33 754 (56·4%) were female and 26 052 (43·6%) were male, with a median age of 26·7 years (IQR 19·3-39·1) at testing date. Among 42 662 participants who initially tested HIV negative and were recontacted, 29 702 (69·6%) underwent repeat HIV testing and were included in the incidence analysis. In this group, over 182 112 person-years of observation, we observed 4852 HIV seroconversions. From 2013 to 2018, overall annual HIV incidence rates declined by 52·2% in males and 36·9% in females. We found no evidence of a continued downward trend in HIV incidence between 2019 and 2025 among either females or males. After a period of substantial decline (from 2011 to 2018), population detectable viraemia increased significantly from 2019 to 2025 by 9·6 percentage points (95% CI 5·4-13·8), remaining an estimated 30·7 percentage points (95% CI 27·2-34·3) below the UNAIDS 95-95-95 population viral suppression target. The incidence-to-prevalence ratio decreased substantially across consecutive survey rounds, from 0·132 (95% CI 0·114-0·152) in 2006 to its lowest recorded value of 0·034 (95% CI 0·028-0·042) in 2022, representing an overall 74·2% decline. After 2022, the ratio stagnated above the epidemic control benchmark of 0·03. INTERPRETATION/CONCLUSIONS:These epidemic metrics show that progress towards HIV epidemic control is faltering in KwaZulu-Natal, South Africa. The tools to reverse this trajectory are available; the challenge now is to ensure their sustained and effective implementation through coordinated action across research, policy, government, civil society, and international funding partners. We can, and we should, change course now if we want to achieve an AIDS-free generation in South Africa and the world. FUNDING/BACKGROUND:National Institute of Mental Health and Wellcome Trust.
PMID: 42843388
ISSN: 2352-3018
CID: 6073979
HIV diagnosis and treatment status in individuals dying from HIV in Zimbabwe, Malawi, and South Africa: A model comparison analysis
Bansi-Matharu, Loveleen; Citron, Daniel T; Martin-Hughes, Rowan; Moolla, Haroon; Stover, John; Pickles, Michael; Mangal, Tara; Smith, Jenny; Mugurungi, Owen; Kubyana, Mmatlou Simeon; Taramusi, Isaac; Cambiano, Valentina; Mpofu, Amon; Ten Brink, Debra; Mudimu, Edinah; Apollo, Tsitsi; Bershteyn, Anna; Chewere, Linley; Dimitrov, Dobromir; Macheso, Stephen; Johnson, Leigh F; Phillips, Andrew
BACKGROUND:Antiretroviral therapy (ART) has greatly reduced HIV-related mortality and improved life expectancy in sub-Saharan Africa since the early 2000s. However, HIV-related mortality remains high. To guide intervention priorities, we used seven established HIV simulation models to identify where in the HIV care cascade deaths occur in Zimbabwe, Malawi, and South Africa. This multi-model approach provided a more comprehensive and robust assessment than could be achieved using any single modelling approach. METHODS AND FINDINGS/RESULTS:To assess alignment, each model generated key HIV metrics from 2000 to 2045, including total population, HIV prevalence, annual new infections, and proportions of people with HIV (PWH) who were diagnosed, on ART, and virally suppressed. HIV-related deaths were estimated annually and categorised by whether they occurred in individuals who were (1) undiagnosed, (2) diagnosed but had not yet started ART, (3) on ART, or (4) had interrupted ART. The models showed strong consistency with population estimates and HIV prevalence across the different settings. There was, however, variation in the absolute number of HIV-related deaths between models; in Zimbabwe in 2025, this ranged from 3,666 to 17,475; in Malawi from 4,580 to 17,835; and in South Africa from 39,470 to 114,968. In Zimbabwe, all models consistently indicated that PWH receiving ART made up the largest proportion of HIV-related deaths, though this proportion differed across models, ranging from 35% to 64%. This was followed by HIV-related deaths amongst those who had interrupted ART, ranging from 17% to 29%. Similar trends were seen in Malawi. In South Africa, a high proportion of HIV-related deaths occurred amongst people who had interrupted ART (23% to 74% in 2025) as well as those who were currently receiving ART (23% to 56%). Models are reliant on empirical data and limited data availability-in this instance, lack of national death registries-is a key constraint on modelling studies. CONCLUSION/CONCLUSIONS:Absolute numbers of HIV-related deaths vary substantially between models, highlighting wider issues around ascertainment of death in the region. However, our results do consistently show that most deaths are occurring amongst PWH on ART in Zimbabwe and Malawi, and amongst those who have interrupted treatment in South Africa, suggesting interventions around adherence counselling and retention in care need to be prioritised.
PMCID:13561354
PMID: 42721221
ISSN: 1549-1676
CID: 6072255
Cost-Effectiveness and Impact of Depression Treatment Implementation on HIV Outcomes in Western Kenya: A Mathematical Modelling Study
Citron, Daniel T; Kim, Hae-Young; Kasujja, Roscoe; Musanje, Khamisi; Mwalili, Samuel M; Gathungu, Duncan Kioi; Wambui, Peris; Chambwe, Chikumbi; Platais, Ingrida; Assefa, Frey B; Jeetoo, Mellesia; Braithwaite, R Scott; Bershteyn, Anna
INTRODUCTION/BACKGROUND:In eastern, central and southern Africa, HIV is a leading cause of mortality, and both HIV and depression contribute substantially to morbidity. Depression can impede effective HIV treatment and prevention, yet access to depression treatment remains limited. We estimated the impact and cost-effectiveness of scaling up depression screening and treatment to different population segments in western Kenya . METHODS:We adapted a previously validated HIV transmission model for western Kenya (EMOD-HIV) to include age- and sex-specific depression incidence, remission and recurrence. The model incorporated depression's effects on HIV risk; HIV testing and linkage to care; antiretroviral therapy (ART) adherence; and ART retention. We evaluated four depression screening and treatment scale-up strategies for adults aged 15+ years: (1) universal screening/treatment for all adults; (2) co-administering depression and HIV screening; (3) screening ART recipients; and (4) screening ART recipients with unsuppressed viral load. We assumed 62% depression treatment efficacy and calculated costs from the provider perspective, including US$3.35 for depression screening and US$20.32 per person for psychotherapy; future costs were discounted at 3%, and costs were varied in sensitivity analyses. We calculated incremental cost-effectiveness ratios as the cost (2024 USD) of depression screening and treatment per overall and HIV-related disability-adjusted life-year (DALY) averted. RESULTS:Without depression treatment, we projected 129,000 new HIV infections, 95,900 HIV-related deaths and 1.83 M depression episodes between 2025 and 2035. Universal screening had the highest impact, averting 29.3% (95% CI 29.2%-29.3%) of person-years lived with depression, 2.8% (95% CI 2.6%-3.1%) of HIV acquisitions and 1.4% (95% CI 1.3%-1.6%) of HIV deaths. The cost-effectiveness of universal screening and treatment was US$1291 per DALY averted (95% CI: $1288-1296). Screening ART clients was most cost-effective at $744 per DALY averted (95% CI: $730-760), followed by screening ART clients with unsuppressed viral load at $752 per DALY averted (95% CI: $710-799). Co-administering HIV and depression was dominated by other strategies. CONCLUSIONS:Integrating depression interventions into HIV care could substantially reduce both depression and HIV burden. Cost-effective scale-up could initially focus on individuals with unsuppressed viral load, then to all ART recipients, and finally expand to communities.
PMCID:13535130
PMID: 42681936
ISSN: 1758-2652
CID: 6071960
Preferences for characteristics of contraceptive methods: a large, multi-country discrete choice experiment
Kim, Hae-Young; Church, Fred; Chang, LinChiat; Berhanu, Della; Kinuthia, John; Bershteyn, Anna
BACKGROUND:Nearly half of global pregnancies are unintended. Contraceptive use is preference-sensitive, including concerns about convenience, privacy and side effects (eg, irregular bleeding, weight gain). We conducted a multi-country study examining women's preferences for attributes of current and potential future modern hormonal contraceptives using a discrete choice experiment (DCE). METHODS:Between April and October 2022, we recruited nationally representative samples of women of reproductive age from seven countries (Burkina Faso, Nigeria, Ethiopia, Kenya, Zambia, Pakistan and the USA) using multi-stage random cluster sampling from national census enumeration areas. The DCE comprised six attributes of hormonal contraceptives: format (ie, mode of administration: injection, implant, etc), dosing interval, provider-administration versus self-administration, effect on menstruation, effect on weight and time from discontinuation until return to fertility. Mixed logit models were fitted separately by country to estimate the relative preference weights (β) for each attribute level. RESULTS:Across 20 068 participants, format was the strongest driver of preferences. Injectables were most preferred in Kenya (β=0.44, 95% CI 0.25 to 0.63), Pakistan (β=0.55, 95% CI 0.29 to 0.81), Ethiopia (β=0.64, 95% CI 0.38 to 0.90) and Zambia (β=0.39, 95% CI 0.20 to 0.58). Oral pills were most preferred in the USA (β=0.78, 95% CI 0.58 to 0.98), Burkina Faso (β=0.43, 95% CI 0.27 to 0.59) and Nigeria (β=0.55, 95% CI 0.40 to 0.70). Intrauterine devices and vaginal rings were less preferred in all countries. Menstrual bleeding changes and dosing interval were secondary drivers, with longer-acting methods modestly preferred and ongoing irregular bleeding modestly non-preferred. Avoiding weight gain was significantly preferred in several countries, most strongly in Pakistan (β=0.56, 95% CI 0.44 to 0.67) and the USA (β=0.42, 95% CI 0.31 to 0.53). CONCLUSIONS:In this large, multi-country study, reproductive-age participants expressed strong, heterogeneous preferences for contraceptive format, and in some settings, avoiding weight gain side effects. These findings can support preference-aligned contraceptive product development.
PMCID:13504926
PMID: 42637271
ISSN: 2059-7908
CID: 6071757
How has mental health impacted the HIV epidemic and how has the HIV epidemic impacted mental health in Western Kenya? A mathematical modelling study
Citron, Daniel; Kim, Hae-Young; Kasujja, Roscoe; Mwalili, Samuel; Gathungu, Duncan; Chambwe, Chikumbi; Platais, Ingrida; Assefa, Frey B; Braithwaite, R Scott; Bershteyn, Anna
BACKGROUND:In eastern and southern Africa, HIV and depression lead to substantial morbidity and mortality. Each condition affects the other: people living with HIV (PLHIV) have higher depression rates, while depression increases HIV acquisition and hinders treatment. The combined impact of HIV-depression interactions on HIV and mental health remains poorly understood. METHODS:We adapted the EMOD-HIV simulation model to incorporate depression incidence, recovery and relapse. We modelled a bidirectional scenario between HIV and depression: HIV increased depression incidence; depression increased HIV incidence and reduced HIV care outcomes. In a counterfactual scenario, all HIV-depression interactions were removed. We estimated how interactions impacted depression episodes, HIV acquisitions, HIV-related deaths and HIV treatment benefits in a high-prevalence region of Western Kenya, 1985-2035. RESULTS:Without interactions, the model projected 1.23 million (95% CI 1.21M to 1.24M) HIV acquisitions, 658 000 (95% CI 650 000 to 666 000) HIV deaths and 12.88 million (95% CI 12.87M to 12.89M) depression episodes. HIV-depression interactions increased depression episodes by 9.76% (95% CI 9.67% to 9.87%), HIV acquisitions by 12.3% (95% CI 12.0% to 12.6%) and HIV deaths by 12.5% (95% CI 12.2% to 12.9%). These interactions also diminished HIV treatment benefits, with 7.72% (95% CI 7.39% to 8.07%) fewer HIV acquisitions and 3.88% (95% CI 3.71% to 4.05%) fewer deaths averted per person-year on treatment. In secondary analyses, increased depression incidence among PLHIV had the greatest effect on HIV outcomes, contributing 7.26% of acquisitions and 7.55% of deaths. CONCLUSION/CONCLUSIONS:HIV-depression interactions have worsened both epidemics. Depression's effects on HIV incidence have been especially deleterious, while its effect on HIV care engagement is increasingly important.
PMID: 42613093
ISSN: 2059-7908
CID: 6071457
Cost-Effectiveness of Differentiated Service Delivery for HIV Treatment: A Combined Mathematical Modeling Study of Four African Settings
You, Shiying; Kim, Hae-Young; Phillips, Andrew N; Citron, Daniel T; Kaftan, David; Platais, Ingrida; Bansi-Matharu, Loveleen; Cambiano, Valentina; Nichols, Brooke E; Jo, Youngji; Braithwaite, Ronald S; Mudimu, Edinah; Bershteyn, Anna
BACKGROUND/UNASSIGNED:Differentiated service delivery (DSD) is increasingly available for HIV treatment. DSD has been shown to improve treatment retention, but DSD modalities incur higher costs than the clinic-based standard-of-care (SoC). We conducted a cost-effectiveness (CE) analysis to assess what DSD modalities, in what settings, would constitute an efficient use of limited HIV program resources. METHODS/UNASSIGNED:) to project HIV trends (incidence, prevalence, mortality), disability-adjusted life years (DALYs), and costs (2021 USD) arising from DSD versus SoC over 2022-2062 in four settings: South Africa, Malawi, Zambia, and a collective representation of African low- and middle-income countries (LMICs). We compared three DSD modalities: healthcare worker-managed community adherence groups (CAG), client-managed urban adherence group (UAG), and home ART delivery (HomeART). We calculated incremental cost-effectiveness ratios (ICERs) of DSD versus SoC from the health system perspective using country-specific CE thresholds, and performed one-way sensitivity analyses for key assumptions. RESULTS/UNASSIGNED:Community adherence groups (ICER: $274-$604/DALY averted) and UAG (ICER: $590-$720/DALY averted) were cost-effective for all country/model settings. HomeART was dominated by UAG in all settings. In nearly all settings, CE estimates of CAG were robust to uncertainty in DSD effectiveness (except Zambia), DSD costs, CE threshold (except South Africa), HIV-associated disability weights, and discount rates. Cost-effectiveness of UAG was highly sensitive to uncertainty in DSD effectiveness in all settings. CONCLUSIONS/UNASSIGNED:Community adherence groups and UAG can provide cost-effective alternatives to the clinic-based SoC in multiple African settings.
PMCID:13280640
PMID: 42325653
ISSN: 2328-8957
CID: 6055172
How do social network models compare to all-to-all models for forecasting tuberculosis epidemics? A mathematical modeling study
Milali, Masabho P; Kim, Hae-Young; Corliss, George F; Bershteyn, Anna
BACKGROUND:Mathematical models guide tuberculosis (TB) target-setting, yet most assume homogeneous "all-to-all" mixing. We compared projected intervention impacts between an all-to-all compartmental model and a Barabási-Albert (BA) scale‑free social network model under otherwise identical disease assumptions. METHODS:We calibrated transmission parameters so both models produced similar baseline trends, then introduced vaccination (coverage 30-70%; efficacy 80-95%) and treatment (20-50% increases in recovery) after a 400‑day burn‑in. Outcomes were assessed 300 days post‑intervention. RESULTS:Under 60% coverage, increasing vaccine efficacy from 80% to 95% yielded smaller projected reductions in active TB with the network model than with all‑to‑all mixing. Treatment improvements showed the same pattern: lower reductions under the network than the all‑to‑all model at modest efficacy, converging at high efficacy/coverage. Findings were robust across baseline prevalence scenarios. CONCLUSIONS:Accounting for social networks can attenuate projected impacts for sub‑optimal TB interventions. Forecasts and target‑setting should include sensitivity to social network structure.
PMCID:13042644
PMID: 41920933
ISSN: 1932-6203
CID: 6021542
Health Benefits of Screening for Co-occurring Alcohol-, Substance-, and Mood-related Conditions for At-Risk Populations: A Mathematical Modeling Study
Bershteyn, Anna; Zhou, Qinlian; Charles, Dyanna; Jeetoo, Mellesia; Khan, Maria R; Justice, Amy C; Chichetto, Natalie E; Marshall, Brandon D L; Gordon, Adam J; Crystal, Stephen; Bryant, Kendall J; Braithwaite, R Scott
BACKGROUND:Co-occurring alcohol, substance, and mood-related (CASM) conditions are prevalent, mutually reinforcing, and under-diagnosed contributors to morbidity, mortality, and health disparities. OBJECTIVE:To evaluate screening strategies leveraging the predictive value arising from patterns of CASM co-occurrence in populations with high CASM prevalence. DESIGN/METHODS:Individual-based health risks model validated to predict US life expectancy and causes of death by sex and age decile, including CASM conditions of depression, anxiety, chronic pain, and unhealthy alcohol, tobacco, opioid and stimulant use. The model includes CASM co-occurrence patterns, mutual reinforcement across CASM conditions, and reduced engagement in other preventative care due to CASM. PARTICIPANTS/METHODS:Veterans Aging Cohort Study (VACS), a large longitudinal cohort of in-care US veterans. INTERVENTIONS/METHODS:(1) Screening alcohol, tobacco, and/or depression symptoms; (2) adding further screening of CASM conditions likely to co-occur with those screened positive, with variation in the minimum co-occurrence rate; (3) screening all CASM conditions (hypothetical maximum). MAIN MEASURES/METHODS:Estimated life expectancy (LE) and quality-adjusted life-years (QALYs). KEY RESULTS/RESULTS:The maximum strategy added 0.52 years to estimated LE (95% CI: 0.51 - 0.54) and 0.68 QALYs/person (95% CI: 0.67 - 0.69). Screening individual CASM conditions added a small fraction of this benefit, the largest LE gain from tobacco screening: 0.08 years (95% CI: 0.07 - 0.09). Screening for depression, alcohol, and tobacco provided 34.6% of the maximum strategy's LE gain (0.19 years, 95% CI: 0.17 - 0.20). Additionally screening conditions with moderate (≥ 20%) probability of co-occurring with those already screened positive provided 84.8% of the maximum strategy's LE gain. Screening all CASM conditions if depression, alcohol, and/or tobacco screened positive provided 86.6% of the maximum strategy's LE gain. CONCLUSIONS:Compared to common practice of screening one or few CASM conditions, large health benefits are possible by further assessing CASM conditions most likely to co-occur with those already screening positive, improving health without increasing up-front screening burden in populations with high CASM prevalence.
PMID: 41741860
ISSN: 1525-1497
CID: 6010222
Using HIV antibody measurements to detect viral load rebound: analysis from an analytic treatment interruption study in the United States
Bershteyn, Anna; You, Shiying; Epstein-Shuman, Adam; Gotthold, Zoe; Kim, Hae-Young; Yamamoto, Nao; Kaftan, David; Chun, Tae-Wook; Laeyendecker, Oliver
OBJECTIVES/OBJECTIVE:HIV viral load (VL) testing using polymerase chain reaction (PCR) is a mainstay of treatment monitoring, but is technically demanding, time-consuming, and costly. We investigated whether antibody measurements can detect VL rebound, leveraging a recent analytic treatment interruption (ATI) study, NCT03225118. METHODS:We tested longitudinal specimens in N=22 ATI participants (91% male, 38-61 year age range, 2.1-15.9 years VL suppression pre-ATI) using Limiting Antigen (LAg) antibody assays, measured as normalized optical density (ODn). We used Bayesian inference to fit linear mixed effects models, including time between first detectable VL and ODn rise, time between peak VL and peak ODn, and ODn rate-of-change after VL re-suppression. RESULTS:LAg ODn increased 4.36 weeks (95% CI: 3.58, 5.79) after treatment interruption and 2.78 weeks (95% CI: 1.94, 4.15) after VL became detectable. ODn peaked 1.03 weeks (95% CI: 0.25, 1.93) after VL peaked, increasing 1.70 fold (95% CI: 1.39, 2.08) compared to pre-interruption. After VL re-suppression, ODn declined by -0.015 units per week (95% CI: -0.017, -0.013) over one year of follow-up. CONCLUSIONS:LAg antibody levels rose in all participants 2-4 weeks after VL detection in treatment interruption. Longitudinal antibody measurements could support facile, rapid, low-cost HIV treatment monitoring.
PMID: 41791480
ISSN: 1878-3511
CID: 6009322
Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries
Silhol, Romain; Booton, Ross D; Mitchell, Kate M; Stannah, James; Stevens, Oliver; Dimitrov, Dobromir; Bershteyn, Anna; Johnson, Leigh F; Kelly, Sherrie L; Kim, Hae-Young; Maheu-Giroux, Mathieu; Martin-Hughes, Rowan; Mishra, Sharmistha; Stone, Jack; Stuart, Robyn; Stover, John; Vickerman, Peter; Wilson, David P; Baral, Stefan; Donnell, Deborah; Imai-Eaton, Jeffrey W; Boily, Marie-Claude
BACKGROUND:Characterising disparities in HIV infection across populations by gender, age, and HIV risk is key information to guide intervention priorities. We aimed to assess how indicators measuring HIV acquisitions, transmissions, or potential long-term infections influence estimates of the contribution of different populations to new infections, including key populations (including female sex workers, their clients, men who have sex with men). METHODS:) measured the proportion of new infections averted if transmission involving a specific population was blocked over a specific time period. We compared estimates of the four indicators across seven populations and 15 settings and assessed if the contribution of specific populations ranked differently across indicators for ten settings. FINDINGS/RESULTS:), whereas more infections were transmitted than acquired in non-key population men aged 25 years and older (median 1·4 times more) and clients of female sex workers (1·6 times more) in all but one model. Estimates of the 10-year tPAFs accounting for transmission in the long-term were substantially larger than the direct transmission indicator for all populations, especially for female sex workers (2·0 times higher). INTERPRETATION/CONCLUSIONS:Indicators that reflect HIV acquisitions and transmissions in the short and long term can be used to capture the complexity of HIV epidemics across different populations and timeframes. The added nuance would improve the effectiveness of the HIV prevention response across all populations at risk. FUNDING/BACKGROUND:US National Institutes of Health and UK Medical Research Council. TRANSLATION/UNASSIGNED:For the French translation of the abstract see Supplementary Materials section.
PMID: 41275868
ISSN: 2352-3018
CID: 5967712